Clinical Trials Browser

INDUSTRY × Breast Neoplasms × dalpiciclib × Clear all

NCT07207070 2025-12-30

A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.

Phase 3 Recruiting

Breast Neoplasms

NCT06613373 2024-09-25

An Exploratory Clinical Study of CDK4/6i Dalpiciclib Combined With AI Neoadjuvant Therapy for Stage II-III HR+/HER2- Breast Cancer

Phase 4 Not yet recruiting

Breast Neoplasms